Decitabine Plus a JAK-Inhibitor

A Phase 2 Trial Investigating Decitabine in Combination With a JAK-Inhibitor as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Patients With Accelerated/Blast Phase Myeloproliferative Neoplasms

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
25 patients (estimated)
Sponsors
Fred Hutchinson Cancer Research Center
Tags
Hypomethylating Agents (HMA), JAK1 Inhibitor, JAK2 Inhibitor
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1651
NCT Identifier
NCT04282187

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.